<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02345057</url>
  </required_header>
  <id_info>
    <org_study_id>CS3150-B-J204</org_study_id>
    <nct_id>NCT02345057</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Type 2 Diabetic Subjects With Microalbuminuria</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Subjects With Type 2 Diabetes Mellitus and Microalbuminuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, placebo-controlled, double-blind, multi-center study to evaluate
      efficacy and safety of different doses of CS-3150 compared to placebo in Japanese Type 2
      Diabetes Mellitus and Microalbuminuria.

      The Primary endpoint is the change from baseline in urinary albumin to creatine ratio (UACR).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in urinary albumin to creatine ratio (UACR)</measure>
    <time_frame>Baseline to end of Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transition from microalbuminuria to normoalbuminuria</measure>
    <time_frame>Baseline to end of Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in renal function</measure>
    <time_frame>Baseline to end of Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum potassium</measure>
    <time_frame>Baseline to end of Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">365</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>CS-3150 0.625 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One CS-3150 0.625 mg tablet and one placebo tablet to match CS-3150 tablet administered orally, once daily after breakfast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CS-3150 1.25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two CS-3150 0.625 mg tablets administered orally, once daily after breakfast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CS-3150 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One CS-3150 2.5 mg tablet and one placebo tablet to match CS-3150 tablet administered orally, once daily after breakfast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CS-3150 5.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two CS-3150 2.5 mg tablets administered orally, once daily after breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two placebo tablets to match CS-3150 tablet, administered orally, once daily after breakfast.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS-3150</intervention_name>
    <arm_group_label>CS-3150 0.625 mg</arm_group_label>
    <arm_group_label>CS-3150 1.25 mg</arm_group_label>
    <arm_group_label>CS-3150 2.5 mg</arm_group_label>
    <arm_group_label>CS-3150 5.0 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>CS-3150 0.625 mg</arm_group_label>
    <arm_group_label>CS-3150 2.5 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with type 2 diabetes mellitus

          -  Male or female subjects aged 20 years or older at informed consent

          -  Subjects with urinary albumin to creatine ratio (UACR) ≥ 45 mg/g Cr and &lt; 300 mg/g Cr

          -  Estimated glomerular filtration rate by creatinine (eGFRcreat) ≥ 30 mL/min/1.73 m^2

          -  Subjects treated with angiotensin-converting enzyme inhibitor (ACEi) or angiotensin
             receptor blocker (ARB) for at least 3 months prior to treatment period

        Exclusion Criteria:

          -  Type 1 diabetes

          -  HbA1c (NGSP) &gt;=8.4%

          -  Secondary glucose intolerance

          -  Subjects diagnosed with non-diabetic nephropathy

          -  Nephrotic syndrome

          -  Secondary hypertension or malignant hypertension

          -  Serum potassium level in any of the following categories: For subjects with eGFRcreat
             of ≥ 45 mL/min/1.73 m^2, serum potassium level of &lt; 3.5 mEq/L or ≥ 5.1 mEq/L; For
             subjects with eGFRcreat of ≥ 30 mL/min/1.73 m^2 and &lt; 45 mL/min/1.73 m^2, serum
             potassium level of &lt; 3.5 mEq/L or ≥ 4.8 mEq/L
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Kumamoto</city>
        <zip>862-0976</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2015</study_first_submitted>
  <study_first_submitted_qc>January 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <last_update_submitted>September 22, 2016</last_update_submitted>
  <last_update_submitted_qc>September 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Nephropathy</keyword>
  <keyword>mineralocorticoid receptor antagonist</keyword>
  <keyword>CS-3150</keyword>
  <keyword>Japanese</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

